Shares of Planet Labs (PL) tumbled as much as 9.3% on May 29, trading near $46.63, as traders cashed in profits from a jaw-dropping run that pushed the satellite-imaging company to within cents of its 52-week high of $51.76. Over the past 52 weeks, PL has traded between a high of $51.76 and a low of $3.66 — meaning the stock has risen more than tenfold from its bottom. The pullback sets the stage for a high-stakes earnings report on June 4 that will either validate or deflate one of the market's most aggressive growth stories.
A SpaceX-Fueled Frenzy Set the Bar Too High, Too Fast
The primary catalyst for the recent surge was the massive hype surrounding the SpaceX IPO; SpaceX officially filed its S-1 prospectus for a long-awaited public debut. That lifted the entire space sector, and internal technical dynamics amplified the move — short interest dropped from 39.1 million shares to 32.2 million, leaving just 11.2% of the float held short. When borrowed shares get bought back at the same time as momentum traders pile in, the result is a price spike that outruns fundamentals.
The Business Is Improving, But the Valuation Has Leapt Far Ahead
Planet Labs boasts a $900 million backlog, accelerating 41% Q4 revenue growth, four consecutive quarters of positive adjusted EBITDA (a measure of operating profitability before non-cash charges), and annual free cash flow of $52.9 million. Yet full-year revenue was $307.7 million against losses of $246.9 million , and the stock now trades at roughly 14–15× projected fiscal 2027 sales after a 300% appreciation.
The average analyst price target sits at just $35.50 — about 31% below the current price.
Options Markets Are Bracing for a Big Swing Either Way With implied volatility pricing in a roughly 10% post-earnings move, the June 4 report is effectively a coin-flip event for short-term holders. Management guided Q1 fiscal 2027 revenue of $87–$91 million, representing roughly 34% year-over-year growth. Anything short of a beat-and-raise could trigger another leg down, because the stock has already priced in an optimistic scenario.
Defense Contracts Are Real, But Profits Are Not — Yet
New multi-year, seven-figure government deals with Greece and the Czech Republic represent recurring, government-grade revenue that smooths out lumpier commercial cycles.
Wedbush recently hiked its price target from $40 to $50 with an Outperform rating, leaning on defense traction and AI-driven growth. But revenue over the last year was about $307.7 million, and margins remain deeply negative. Until losses narrow decisively, the stock's altitude depends entirely on investors' willingness to keep paying for the future.